Why ORAL fluconazole/Diflucan CANNOT Cure Rosacea

OXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXO
ADVISORY DISCLAIMER:
All theories offered here, concerning how or why [FLUCONAZOLE 1% SOLUTION],
(i.e. [DMSO + fluconazole/Diflucan]) works to cure rosacea, are only
well-educated, first-hand experience oriented hypotheses. Confidence remains
extremely high, that 100% of all cases of rosacea are curable by this topically
applied medication, whether or not these theories of how or why it works are
accurate and/or correct.
OXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXO

For Everyone,
As referred to in rosacea-cure message #192, repetitive, long-term use of at
least several months was needed, with repeated TOPICAL applications of
[FLUCONAZOLE 1% SOLUTION], to produce the final, 100% cure of my rosacea. Also
referred to, was the fact that the toxicity, (i.e. potentially very bad
side-effects, such as permanent liver damage and/or death, as in rosacea-cure
message #111), make it highly unlikely that ORALLY ADMINISTERED
fluconazole/Diflucan could ever successfully be administered in the repetitive,
sometimes daily, chronic high-dosage usage required, without causing toxic, even
possibly deadly effects on the whole body.

But in addition, aside from the high toxicity, and very bad potential
side-effects of ORALLY ADMINISTERED fluconazole/Diflucan, there is another, even
more significant reason why ORALLY ADMINISTERED fluconazole/Diflucan could never
cure rosacea.
The statement below, involving a clinical study on cats with viral infections,
clarifies why ORALLY ADMINISTERED fluconazole/Diflucan would never be effective
in curing rosacea, while a TOPICALLY APPLIED (DMSO + fluconazole/Diflucan)
liquid mixture does cure rosacea.

Unlike a bacterial infection, a virus must penetrate individual human cell
membranes, in order to go inside the human cells, and thereby multiply. The
human cells are destroyed by this process. The study explained below, proves
plainly, and conclusively, that a (DMSO + antiviral drug) mixture killed the
viral infection, which was not killed by the DMSO alone, or by the antiviral
drug alone. This strongly implies, that the DMSO is acting to allow the
antiviral drug TO GO INSIDE EACH INDIVIDUAL CELL, (to kill the virus), but the
antiviral drug alone cannot penetrate the cells, even though it may circulate
throughout the systemic system, (i.e. the entire bloodstream).

As rosacea is most likely caused by a parasitical fungal infestation, it is very
likely that this "parasite network" has evolved a way to integrate itself into,
(i.e. partially inside of), the individual human cells, making it difficult or
impossible for any ORALLY ADMINISTERD drug, (such as fluconazole/Diflucan), to
reach it and/or to kill it COMPLETELY. Since the TOPICALLY APPLIED (DMSO +
fluconazole/Diflucan) liquid mixture can most likely penetrate each human cell,
this is likely the main reason why it is effective in killing this parasite.

Subsequently, this allows the human immune system to further attack it, and get
rid of it completely, which may take two to six weeks for the immune system to
accomplish. Up to six weeks is required, in each "killing cycle", because this
parasite has had decades of slow growth to establish itself in the skin, and the
immune system is finally being allowed to work, to remove this "established
parasitical structure". Also, it takes two to six weeks, for new, healthy skin
to completely grow in to replace this destroyed parasite and the skin cells it
has damaged.
OCULAR ROSACEA
There is the further very high probability, that this medication, when applied
only on the skin of the face, actually attacks fungal parasitical infestations
throughout the head, (i.e. as in ocular rosacea), and indeed, throughout the
whole body, since some very small percentage of this TOPICALLLY APPLIED [DMSO +
fluconazole/Diflucan] liquid mixture medication is known to enter the
bloodstream, and circulate throughout the body.
The following statement, defining this clinical study, is at URL:
<http://www.dmso.org/articles/information/jacob.htm>

---STATEMENT FOLLOWS---
Another important component of DMSO activity is its synergism with other
therapeutic agents. For example, Charles Dake, D.V.M. (Annals of the NY Academy
of Sciences, 1967, Vol. 141) found that cats with overwhelming viral infection
treated with either DMSO alone or conventional therapy for viral infections all
died. When DMSO was combined with standard antiviral treatment, the figures were
reversed with the majority of the cats surviving.

God Bless,
Dave Fleming

XOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXO
OXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOX

<http://www.dmso.org/articles/information/jacob.htm>
-------FULL TEXT OF THE ABOVE URL FOLLOWS-------
Current Status of DIMETHYL SULFOXIDE (DMSO), March 2002
Stanley W. Jacob, M.D
Gerlinger Professor
o Department of Surgery
o Oregon Health Sciences University
o 3181 S.W. Sam Jackson Park Road
o Mail Code L225
o Portland, Oregon 97201
o (503) 494-8474
o FAX (503) 494-5352
March 2002
DMSO (dimethyl sulfoxide), as a therapeutic principle, was first introduced to
the scientific community in 1963 by a research team headed by Stanley W. Jacob,
MD, at the University of Oregon Medical School.
While DMSO has been called "the most controversial therapeutic advance of modern
times," the controversy seems to be bureaucratic and economic rather than
scientific. Over the past forty years, more than 10,000 articles on the biologic
implications of DMSO have appeared in the scientific literature and 30,000
articles on the chemistry of DMSO have also been published. The results of these
studies strongly support the view that DMSO is a TRULY SIGNIFICANT NEW
THERAPEUTIC PRINCIPLE.
When organ systems are injured or deteriorate, the damaged tissue produces
agents we call "free radicals." These further harm cells and prevent or slow
healing. DMSO is a potent scavenger of these radicals, maintaining the normal
integrity of cells and tissues.

OXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXO
Another important component of DMSO activity is its synergism with other
therapeutic agents. For example, Charles Dake, D.V.M. (Annals of the NY Academy
of Sciences, 1967, Vol. 141) found that cats with overwhelming viral infection
treated with either DMSO alone or conventional therapy for viral infections all
died. When DMSO was combined with standard antiviral treatment, the figures were
reversed with the majority of the cats surviving.
XOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOXOX

At this time, DMSO is a respected, approved pharmaceutical agent in more than
125 countries. In 1970, the FDA approved DMSO for the treatment of
musculoskeletal disorders in dogs and horses. Many veterinarians consider DMSO
to be the most valuable therapeutic substance in their armamentarium.
Additionally in 1978, it was approved by the FDA in humans for the therapy of
Interstitial Cystitis (a painful disabling urinary bladder inflammation). In
many ways, DMSO represents the "aspirin" of our era. If aspirin had been
introduced in 1963 with its multiple properties, it might very well have been
similarly restricted in the scope of its application.
DMSO became prescriptive for humans in the USSR in 1971. Since that time, it has
been widely used in the USSR alone and in combinations. Currently DMSO is
employed in the therapy of various musculo-skeletal problems in Russia. Dr.
Balabanova of the Moscow Institute of Rheumatology estimates that about 50
percent of the Russian arthritic population receives DMSO as a part of their
therapy. There are more than one hundred articles in the world's literature
relating to DMSO and arthritis. These include both clinical results and
mechanisms of action. Among the well-documented pharmacological properties of
DMSO are analgesia, anti-inflammation, softening of scar tissue, hydroxyl
radical scavenging, vasodilation, and stimulation of healing.
An excellent controlled study was completed by the Japanese Rheumatism
Association showing benefit in rheumatoid arthritis (Matsomoto - Annals of NY
Academy of Sciences 1967, Vol. 141, Article 1, 560-569). Twenty university
centers were involved.
One of the most important questions about any medicinal therapy is safety.
Except for nuisance side effects such as odor, the only well-documented,
potentially serious side effect is the occasional patient who is allergic. A
careful review of the published literature on DMSO shows that there is not a
single death that can definitely be attributed to this agent.
Conservatively, hundreds of millions of patients have been safely treated with
DMSO worldwide. DMSO is a substance of extraordinary low toxicity.
In 1965, when the FDA halted evaluation of DMSO in the United States, they had
data in their files on more than 100,000 patients submitted by approximately
1,500 physicians in our country showing safety and effectiveness. The
pharmaceutical companies submitting the aforementioned data were Merck, Syntex,
and Squibb. This occurred in 1965.
When we discuss DMSO, we are talking about an agent that not only relieves pain,
but also has multiple well-documented effects in a variety of illnesses. DMSO
possesses lifesaving potential in stroke and head injuries (JC de la Torre -
Annals of NY Academy of Sciences 1975, vol. 243). In multiple lower animal
studies, DMSO prevents indefinite paralysis following severe spinal cord
contusions. Since 1965, about 300,000 people in this country have sustained
spinal cord injuries. Many remain paralyzed. The early effective use of DMSO
might have prevented theses tragedies. More recently, Karaca (European Journal
of Clinical Pharmacology 1991, vol. 40:113-114) & Kulai (Neurchirurgia 1990,
Vol. 33: 177-180) report on the value of intravenous DMSO in the management of
brain swelling and intracranial pressure in patients with the severe closed head
injury. Currently, we are studying DMSO and fructose diphosphate in rodents for
the therapy of Alzheimer's' Disease.
Today, DMSO is an effective treatment for many illnesses for which we have no
other therapy. It is safer, less expensive, and at least as effective for a
variety of problems for which we are presently using other, less effective, and
more costly treatments. In 1972 the National Academy of Sciences evaluated the
scientific data on DMSO and concluded it was a least as effective as currently
approved treatments for three musculoskeletal inflammatory problems in man.
We have employed a mixture of DMSO and DMSO2 for the therapy of fibromyalgia.
Patients are treated with intravenous, oral, and topical routes. It requires
approximately two months before any benefit occurs. Seventy percent of our
patients with fibromyalgia improve.
Published articles on DMSO have show benefit in the following entities:
Interstitial Cystitis
Scleroderma
Raynaud's Phenomenon
Lupus
Rheumatoid Arthritis
Degenerative Arthritis
Ulcerative Colitis
Chronic Obstructive Pulmonary Disease
Reflex Sympathetic Dystrophy
Diabetic Ulcerations
Burns
Scar Tissue
Adjunct in Plastic Surgery

© 2001-2003 All rights reserved


---------------------------------
Do you Yahoo!?
Yahoo! Search - Find what you’re looking for faster.

[Non-text portions of this message have been removed]